drugset / Trial / NCT07528352

External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL

NCT07528352

Phase 1 Recruiting 12 enrolled University of Utah
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Timeline

Start
2026-06-01
Primary completion
2030-06
Completion
2031-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Epcoritamab Monoclonal antibody
Subject Glofitamab Monoclonal antibody